Eisai Co., Japan’s fourth-largest drugmaker, said it bought the rights to develop and sell Massachusetts-based Sepracor Inc.’s Lunesta sleeping pill in its home market.
The drug, which has the generic name eszopiclone, is in the first of three stages in Japan of patient studies generally required for regulatory review, Tokyo-based Eisai said Friday.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.